GO:0034125 negative regulation of MyD88-dependent toll-like receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034125 describes any process that stops, prevents, or reduces the frequency, rate, or extent of MyD88-dependent toll-like receptor signaling.
• The MyD88-dependent pathway is the canonical route through which most TLRs activate NF-kB and inflammatory gene expression.
• Negative regulators of this pathway include deubiquitinases such as OTUD4, which removes K63-linked ubiquitin chains from MyD88 and dampens signaling.
• TLR10 acts as a negative regulator of both MyD88-dependent and MyD88-independent TLR signaling.
• MicroRNA-7 negatively regulates TLR4 signaling through FAM177A, illustrating post-transcriptional control of this pathway.
• Dysregulation of negative regulation contributes to inflammatory diseases, liver pathology, and immune evasion, making it a target for CRISPR-based functional studies.
Description
The MyD88-dependent toll-like receptor (TLR) signaling pathway is a central innate immune cascade that detects microbial ligands and initiates inflammatory responses. Toll-like receptors recruit the adaptor protein MyD88, which assembles a signaling complex leading to NF-kB activation and cytokine production. Because excessive or prolonged TLR signaling can damage host tissues, cells employ multiple negative regulatory mechanisms to constrain this pathway. GO:0034125, negative regulation of MyD88-dependent toll-like receptor signaling pathway, captures these inhibitory processes. Understanding this term is essential for researchers studying infection, autoimmunity, and cancer, where TLR signaling must be tightly controlled. Negative regulators such as OTUD4, TLR10, and microRNA-7 have been shown to directly attenuate MyD88-dependent signaling. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, genes, and experimental models relevant to GO:0034125.
negative regulation of MyD88-dependent toll-like receptor signaling pathway At A Glance
| GO ID | GO:0034125 |
|---|---|
| GO term | negative regulation of MyD88-dependent toll-like receptor signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of MyD88-dependent TLR signaling pathway; negative regulation of MyD88-dependent toll-like receptor signalling pathway |
| Major function | Inhibition or dampening of the MyD88-dependent TLR signaling cascade, limiting NF-kB activation and inflammatory cytokine production |
| Key regulators | OTUD4, TLR10, microRNA-7/FAM177A, S-nitrosylation of MyD88 |
| Associated diseases | Inflammatory diseases, liver injury, and conditions driven by excessive TLR signaling |
| Research relevance | Target for CRISPR knockout, point mutation, and overexpression studies to dissect innate immune control |
What Is GO:0034125?
GO:0034125 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of MyD88-dependent toll-like receptor signaling pathway. It encompasses molecular events that inhibit the recruitment of MyD88 to TLRs, disrupt MyD88 complex assembly, remove activating ubiquitin chains, or otherwise suppress downstream NF-kB and MAPK activation. This term is distinct from negative regulation of MyD88-independent TLR signaling, although some regulators such as TLR10 affect both branches.
Why Is negative regulation of MyD88-dependent toll-like receptor signaling pathway Important in Cell Biology?
Negative regulation of MyD88-dependent TLR signaling is critical for preventing chronic inflammation and tissue damage. Without proper inhibitory mechanisms, sustained TLR activation can contribute to autoimmune disorders, sepsis, and liver pathology. The pathway is also relevant to cancer immunology, as TLR signaling in the tumor microenvironment can either promote or suppress tumor progression depending on context. Understanding GO:0034125 helps researchers identify therapeutic targets and design experiments to modulate innate immunity.
• Prevents excessive inflammation by limiting NF-kB activation downstream of TLRs.
• Controls the duration and intensity of innate immune responses to pathogens.
• Dysregulation is linked to inflammatory and autoimmune diseases.
• OTUD4 acts as a phospho-activated K63 deubiquitinase that negatively regulates MyD88-dependent signaling.
• TLR10 functions as a negative regulator of both MyD88-dependent and -independent TLR signaling.
• MicroRNA-7 negatively regulates TLR4 signaling through FAM177A.
• S-nitrosylation of MyD88 retards TLR signal transduction and acute-phase immune responses.
• The pathway is evolutionarily conserved across deuterostomes, highlighting its fundamental importance.
• Endothelial cells use LPS signaling, and negative regulation is relevant to vascular inflammation.
• Liver regeneration is influenced by TLR/MyD88 signaling, indicating roles beyond immunity.
What Happens During negative regulation of MyD88-dependent toll-like receptor signaling pathway?
Inhibition of MyD88 recruitment and complex assembly
In simple terms: This step blocks the adaptor protein MyD88 from joining the TLR signaling complex.
Negative regulation can occur at the level of TLR-MyD88 interaction. For example, TLR10 can inhibit MyD88-dependent signaling by competing or interfering with MyD88 recruitment. Additionally, S-nitrosylation of MyD88 modifies its function and retards signal transduction. These events prevent the formation of an active signaling platform, thereby reducing downstream NF-kB activation.
Deubiquitination of MyD88 and signaling intermediates
In simple terms: Enzymes remove ubiquitin tags from MyD88, which turns off the signal.
OTUD4 is a phospho-activated K63 deubiquitinase that removes K63-linked ubiquitin chains from MyD88, leading to decreased NF-kB activation. This deubiquitination is a key negative regulatory mechanism that directly opposes the activating ubiquitination required for MyD88-dependent signaling.
MicroRNA-mediated suppression
In simple terms: Small RNA molecules reduce the production of proteins needed for TLR signaling.
MicroRNA-7 negatively regulates TLR4 signaling through FAM177A, dampening the pathway at the post-transcriptional level. This illustrates that negative regulation can occur by reducing the abundance of signaling components or their regulators.
Downstream attenuation of NF-kB and MAPK activation
In simple terms: The final outcome is less activation of inflammatory genes.
Ultimately, negative regulation of MyD88-dependent signaling reduces the activation of NF-kB and MAPK pathways, leading to lower expression of pro-inflammatory cytokines. This attenuation is essential for resolving inflammation and preventing tissue damage.
Key Genes Involved in GO:0034125 negative regulation of MyD88-dependent toll-like receptor signaling pathway
The following genes and proteins are experimentally implicated in the negative regulation of MyD88-dependent TLR signaling, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYD88 | Central adaptor protein; its modification or degradation is targeted by negative regulators | Key node for knockout and point mutation studies |
| OTUD4 | Phospho-activated K63 deubiquitinase that removes ubiquitin from MyD88, inhibiting signaling | Direct negative regulator; target for overexpression and KO |
| TLR10 | Negative regulator of both MyD88-dependent and -independent TLR signaling | Inhibitory receptor; knockout increases signaling |
| FAM177A | Mediator of microRNA-7 negative regulation of TLR4 signaling | Post-transcriptional regulator; miRNA target |
| MIR7 | MicroRNA that negatively regulates TLR4 signaling via FAM177A | Non-coding RNA regulator; overexpression studies |
| CD14 | Co-receptor for LPS; its trafficking influences TLR4 signaling | Upstream modulator; KO reduces signaling |
| TLR4 | Primary receptor for LPS; initiates MyD88-dependent signaling | Target for negative regulation studies |
| NFKB1 | Transcription factor downstream of MyD88; readout of pathway activity | Reporter for negative regulation |
| MAPK1 | Kinase downstream of MyD88; contributes to inflammatory gene expression | Readout for pathway inhibition |
| TRAF6 | E3 ubiquitin ligase that activates MyD88 signaling; can be counteracted by deubiquitinases | Target for negative regulation via OTUD4 |
| IRAK4 | Kinase recruited to MyD88; its activity is required for signaling | Potential target for inhibitory mechanisms |
| IRAK1 | Kinase downstream of MyD88; subject to regulatory modifications | Readout for pathway activity |
| TICAM1 | TRIF adaptor for MyD88-independent signaling; not directly in this term | Control for specificity studies |
| TNF | Pro-inflammatory cytokine whose expression is reduced by negative regulation | Functional readout |
| IL6 | Cytokine downstream of NF-kB; reduced by negative regulation | Functional readout |
| IL1B | Cytokine processed via inflammasome; influenced by TLR signaling | Readout for inflammation |
| SOCS1 | Suppressor of cytokine signaling; can inhibit TLR signaling | Potential negative regulator |
| TNFAIP3 | A20 deubiquitinase that inhibits NF-kB; negative regulator of TLR signaling | Target for KO and overexpression |
How Is negative regulation of MyD88-dependent toll-like receptor signaling pathway Regulated?
The negative regulation of MyD88-dependent TLR signaling is itself tightly controlled. OTUD4 is activated by phosphorylation, linking kinase signaling to deubiquitination of MyD88. S-nitrosylation of MyD88 provides a redox-sensitive mechanism to retard signaling. MicroRNA-7 levels can be regulated by inflammatory stimuli, creating a feedback loop. Additionally, TLR10 expression can be modulated during infection, affecting the balance between activation and inhibition. These layers of regulation ensure that the pathway is transiently activated and then promptly shut down.
negative regulation of MyD88-dependent toll-like receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OTUD4 | Inflammatory diseases; negative regulation of TLR signaling | Knockout and overexpression in macrophages |
| TLR10 | Autoimmune and inflammatory conditions | Knockout mice and human cell lines |
| MIR7 | TLR4-driven inflammation | Overexpression and inhibition in epithelial cells |
| MYD88 | Liver injury and regeneration | Liver-specific knockout mice |
| TNFAIP3 | Autoimmunity and lymphoma | Knockout and point mutation models |
Inflammatory and autoimmune diseases
Excessive MyD88-dependent TLR signaling contributes to chronic inflammation and autoimmunity. Negative regulators such as OTUD4 and TLR10 are critical for preventing uncontrolled inflammation. Loss of these regulators can exacerbate disease, making them potential therapeutic targets.
Liver injury and regeneration
TLR/MyD88 signaling contributes to murine liver regeneration, and negative regulation may influence the balance between injury and repair. Dysregulated negative regulation could impair liver recovery after damage.
Cancer and tumor microenvironment
TLR signaling in cancer can promote or inhibit tumor growth depending on context. Negative regulators of MyD88-dependent signaling may shape the inflammatory tumor microenvironment and influence responses to immunotherapy.
Infectious diseases
Pathogens can exploit negative regulatory mechanisms to evade immune responses. Understanding how negative regulation is manipulated during infection may inform vaccine and therapeutic design.
From negative regulation of MyD88-dependent toll-like receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does OTUD4 negatively regulate MyD88-dependent signaling? | OTUD4 knockout and overexpression cell lines |
| Does TLR10 inhibit MyD88-dependent signaling? | TLR10 knockout and overexpression models |
| Does microRNA-7 suppress TLR4 signaling via FAM177A? | MicroRNA-7 overexpression and FAM177A knockout |
| Does S-nitrosylation of MyD88 retard signaling? | Point mutation of MyD88 nitrosylation sites |
| Does MyD88 signaling affect liver regeneration? | Liver-specific MyD88 knockout mice |
| Is the negative regulation conserved across species? | Comparative genomics in deuterostomes |
How to Study the negative regulation of MyD88-dependent toll-like receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on TLR signaling | Identify negative regulators |
| RNA-seq | Transcriptional changes | Measure inflammatory gene expression |
| Proteomics | Protein abundance and modifications | Detect ubiquitination of MyD88 |
| NF-kB reporter assay | NF-kB activation | Validate negative regulators |
| Co-immunoprecipitation | Protein-protein interactions | Study MyD88 complex assembly |
| Western blot | Protein expression and phosphorylation | Assess signaling intermediates |
| Flow cytometry | Cytokine production in immune cells | Functional readout |
| MicroRNA profiling | miRNA expression levels | Study post-transcriptional regulation |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify negative regulators of MyD88-dependent TLR signaling by selecting for cells with enhanced NF-kB activation. Such screens have the power to uncover novel inhibitors like OTUD4 and TLR10.
RNA sequencing and transcriptomics
RNA-seq measures changes in inflammatory gene expression upon perturbation of candidate negative regulators. This method can reveal the downstream impact of genes such as OTUD4 or TLR10 on the TLR transcriptional program.
Proteomics and ubiquitin analysis
Mass spectrometry-based proteomics can detect ubiquitination and phosphorylation events on MyD88 and associated proteins. This is essential for understanding deubiquitinase mechanisms like OTUD4.
Imaging and reporter assays
NF-kB luciferase reporters and fluorescence microscopy can visualize pathway activity in live cells. These methods are useful for validating negative regulators in real time.
How CRISPR Can Be Used to Study GO:0034125 negative regulation of MyD88-dependent toll-like receptor signaling pathway
Knockout
CRISPR knockout of candidate negative regulators such as OTUD4 or TLR10 can enhance MyD88-dependent signaling, confirming their inhibitory role. Knockout models are essential for loss-of-function studies in macrophages and epithelial cells.
Point Mutation
Point mutations can be introduced into MyD88 to block specific modifications, such as S-nitrosylation sites, to test their role in negative regulation. This approach provides mechanistic insight without altering protein levels.
Knock-in
Knock-in of tagged versions of MyD88 or OTUD4 allows for tracking of protein localization and interactions in live cells. Tagged knock-in models are valuable for proteomic and imaging studies.
Overexpression
Overexpression of negative regulators like OTUD4 or microRNA-7 can suppress TLR signaling, providing gain-of-function evidence. This is useful for validating therapeutic potential.
How EDITGENE Supports negative regulation of MyD88-dependent toll-like receptor signaling pathway Research
Researchers studying negative regulation of MyD88-dependent toll-like receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening the pathway. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of MyD88-dependent toll-like receptor signaling pathway research.
Frequently Asked Questions About negative regulation of MyD88-dependent toll-like receptor signaling pathway
What is GO:0034125?
GO:0034125 is the Gene Ontology term for negative regulation of MyD88-dependent toll-like receptor signaling pathway, describing processes that inhibit this innate immune cascade.
What genes are involved in negative regulation of MyD88-dependent TLR signaling?
Key genes include OTUD4, TLR10, MIR7, FAM177A, and MYD88 itself, as shown in published studies.
How does OTUD4 negatively regulate MyD88 signaling?
OTUD4 is a phospho-activated K63 deubiquitinase that removes ubiquitin chains from MyD88, reducing NF-kB activation.
What is the role of TLR10 in TLR signaling?
TLR10 acts as a negative regulator of both MyD88-dependent and MyD88-independent TLR signaling.
How does microRNA-7 affect TLR4 signaling?
MicroRNA-7 negatively regulates TLR4 signaling through FAM177A, dampening the pathway.
What diseases are associated with dysregulated negative regulation of MyD88 signaling?
Inflammatory diseases, liver injury, and cancer can be influenced by impaired negative regulation.
What experimental models are used to study GO:0034125?
CRISPR knockout, point mutation, knock-in, and overexpression models in macrophages and epithelial cells are commonly used.
Is the MyD88-dependent pathway conserved across species?
Yes, TLR pathway evolution studies show conservation across deuterostomes.
How can I screen for novel negative regulators of MyD88 signaling?
Genome-wide CRISPR knockout screens coupled with NF-kB reporter assays can identify novel inhibitors.
What is the difference between MyD88-dependent and MyD88-independent TLR signaling?
MyD88-dependent signaling uses the adaptor MyD88, while MyD88-independent signaling uses TRIF; some regulators like TLR10 affect both.
Conclusion
GO:0034125 represents a vital layer of control in innate immunity, ensuring that MyD88-dependent TLR signaling is transient and self-limiting. Key negative regulators such as OTUD4, TLR10, and microRNA-7 have been experimentally validated. Dysregulation of this process contributes to inflammatory diseases and liver pathology, making it a compelling area for therapeutic intervention. CRISPR-based models offer powerful tools to dissect these mechanisms and identify new drug targets.
References
- 1. Ciesielska A et al.. 2021. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling.. Cell Mol Life Sci 78(4):1233-1261 PMID: 33057840
- 2. Zhao Y et al.. 2018. OTUD4 Is a Phospho-Activated K63 Deubiquitinase that Regulates MyD88-Dependent Signaling.. Mol Cell 69(3):505-516.e5 PMID: 29395066
- 3. Tassia MG et al.. 2017. Toll-like receptor pathway evolution in deuterostomes.. Proc Natl Acad Sci U S A 114(27):7055-7060 PMID: 28630328
- 4. Chen H et al.. 2021. MicroRNA-7 negatively regulates Toll-like receptor 4 signaling pathway through FAM177A.. Immunology 162(1):44-57 PMID: 32852789
- 5. Dauphinee SM et al.. 2006. Lipopolysaccharide signaling in endothelial cells.. Lab Invest 86(1):9-22 PMID: 16357866
- 6. Into T et al.. 2008. Regulation of MyD88-dependent signaling events by S nitrosylation retards toll-like receptor signal transduction and initiation of acute-phase immune responses.. Mol Cell Biol 28(4):1338-47 PMID: 18086890
- 7. Seki E et al.. 2005. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration.. Hepatology 41(3):443-50 PMID: 15723296
- 8. Jiang S et al.. 2016. TLR10 Is a Negative Regulator of Both MyD88-Dependent and -Independent TLR Signaling.. J Immunol 196(9):3834-41 PMID: 27022193
